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Abstract
Background: Antibodies targeting merozoites are important in protection from malaria. Therefore, merozoite surface
proteins are attractive vaccine candidates. There is a need for robust functional assays to investigate mechanisms of
acquired immunity and vaccine efficacy. To date, the study of merozoite phagocytosis has been confounded by the
complexity and variability of in vitro assays.
Methodology/Principal findings: We have developed a new flow cytometry-based merozoite phagocytosis assay. An
optimized merozoite preparation technique produced high yields of merozoites separated from haemozoin. Phagocytosis
by the undifferentiated THP-1 monocytic cell line was mediated only by Fc Receptors, and was therefore ideal for studying
opsonising antibody responses. The assay showed robust phagocytosis with highly diluted immune sera and strong inter-
assay correlation. The assay effectively measured differences in opsonisation-dependent phagocytosis among individuals.
Conclusions/Significance: This highly reproducible assay has potential applications in assessing the role of opsonic
phagocytosis in naturally acquired immunity and vaccine trials.
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Introduction
Naturally acquired immunity to Plasmodium falciparum malaria
develops over time and exposure, involving both humoral and cell
mediated immune responses. Immunity is non-sterilizing and
results in reduced parasite densities and protection from clinical
disease [1]. Antibodies, particularly IgG1 and IgG3 subclasses, are
crucial components of acquired immunity and develop against
surface antigens of sporozoite, intra-erythrocytic and merozoite
forms of the asexual life cycle[1–3]. The importance of antibodies
for protection against clinical episodes of P. falciparum malaria was
highlighted by passive transfer experiments where c-globulin from
immune African adults afforded protection against severe malaria
to non-immune children [4,5].
Identifying antibody responses to the merozoite surface coat in
human studies has typically involved ELISA-based serology.
However conflicting findings have been reported for various
antigens, with some studies reporting associations between
antibody levels and protection from disease, while others do not
[6]. ELISA methodologies do not discriminate the large propor-
tion of immunoglobulin produced during infection that may bind
antigen or peptide in vitro but may be functionally irrelevant.
Furthermore, antibody affinity and avidity, and the role of
antibody-leukocyte cooperation, are not measured using ELISA
endpoints. Such serology alone provides only limited information
about antigenic targets of acquired immunity. Thus there is a need
for assays better able to measure functionally protective responses
and their antigenic targets.
Currently the only functional assays that have been applied to
the study of acquired immunity to P. falciparum merozoites are
in vitro growth inhibition assays [7,8]. Growth inhibition assays,
which in part are considered to measure merozoite invasion
inhibition, have not always revealed associations with clinical
immunity [9–11]. They also do not examine interactions between
antibody and cellular immunity. Numerous antigens produce an
opsonising antibody response that requires leukocyte co-operation
for anti-parasitic functions [12–14]. Furthermore, several vaccines
under development, such as MSP3-LSP, may require antibody-
leukocyte co-operation to be efficacious [15].
An Antibody Dependent Cellular Inhibition (ADCI) assay has
been used for measurement of opsonising antibody responses [16].
This assay has led to identification of clinically important antigens
such as merozoite surface protein 3 (MSP-3) [14] and GLURP
[13]. In passive transfer experiments, protective immune plasma
inhibited parasite growth in vitro only in the presence of monocytes
in the ADCI assay [16]. However, various limitations have
hampered widespread application of this assay to clinical and
research settings, and associations between assay outcomes and
clinical protection are not yet proven. The basis of the assay
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depends on IgG:monocyte interaction where cytophilic IgG is
essential, resulting in the release of a soluble factor from
monocytes which inhibits the growth of surrounding intra-
erythrocytic parasites [17]. Antibody function is then measured
by reduction in parasite viability, as assessed by giemsa stained
blood smears [16,18], and more recently by flow cytometry
[19,20]. In combination with primary monocytes and the use of
purified IgG, the resulting assay is time consuming, variable and
quite complex. These factors may contribute to the lack of
reproducibility reported for this assay in different settings [21].
Like ADCI, phagocytosis of merozoites also requires cytophillic
IgG and Fc Receptors (FcR). The importance of phagocytosis in
malaria was demonstrated by macrophage depletion in mice,
which abolished acquired immunity despite unchanged antibody
profiles [22]. In human studies, phagocytic opsonising antibody
responses to mature parasitized red blood cells are associated with
reduced risk of placental malaria in primigravidae, secundigrav-
idae and HIV-infected individuals [23,24]. Monocytes, macro-
phages and neutrophils also phagocytose merozoites both in vitro
and in vivo [25–29]. Merozoites are highly exposed to the immune
system and a strong antibody response is mounted against the
merozoite surface coat. Human monoclonal antibodies to a
merozoite surface antigen with strong invasion inhibition activity
in vitro, failed to transfer immunity to mice unless recipients were
transgenic for appropriate FcR [30]. Thus, phagocytosis of
merozoites before they invade red blood cells (RBC) may also be
a mechanism for controlling parasitemia in immune humans.
However, merozoite phagocytosis has been poorly studied, and
it remains unclear whether antibodies promoting phagocytosis of
merozoites confer protection and reduce parasite burden in
humans. A major difficulty lies in the reproducibility of in vitro
merozoite phagocytosis assays. This appears to results from i)
difficulty in isolating intact and viable merozoites for use in in vitro
assays, ii) donor variability in primary phagocytic cells [31], and iii)
difficulty in discerning FcR- from non-FcR-mediated phagocyto-
sis. Collectively, these factors make current merozoite phagocytosis
assays difficult to standardize and apply to cohort studies and
clinical trials for the analysis of association with parasitological and
clinical risk.
To address these limitations we have developed a simplified
phagocytosis assay to investigate the functional activity of human
antibodies. A recently developed isolation technique, adapted to
phagocytosis assays, enabled purification of large yields of
fluorescent merozoites separated from haemozoin. Utilising
undifferentiated THP-1 cells allowed highly reproducible mea-
surement of phagocytosis of opsonised merozoites mediated by Fc
Receptors [32,33]. These improvements, in addition to a flow
cytometry readout, have resulted in a method returning high inter-
assay reproducibility and sufficient throughput that is suitable for
vaccine trials and for large longitudinal cohort studies.
Materials and Methods
Collection of Plasma and Serum Samples
Plasma samples utilized for this study were collected from
children (5–12 yrs) and adults (18–53 yrs) from Madang Province
on the north coast of Papua New Guinea (PNG). The study was
approved by the Medical Research Advisory Committee, Papua
New Guinea Ministry of Health, The Walter and Eliza Hall
Institute Human Research Ethics Committee (project number 04/
04). Written consent was obtained from parents/guardians of all
participants. Non-immune plasma from anonymous healthy
Western Australian adult donors was isolated from whole blood
donated by the Australian Red Cross Blood Service.
THP-1 Monocyte Cell Line
The human monocytic cell line THP-1 (TIB-202, American
Type Culture Collection (ATCC) was maintained in RPMI-1640
supplemented with 10% foetal bovine serum (FBS) and 55 mM 2-
mercapthoethanol (THP-1 medium), and maintained below a
density of 56105 cells/mL.
P. falciparum 3D7 Culture and Merozoite Isolation
P. falciparum 3D7 parasites were cultured at 4% hematocrit in
RPMI-1640 supplemented with 25 mg/mL HEPES, 2 mg/mL
sodium bicarbonate, and 10% pooled human serum (parasite
medium). Cultures were maintained at 37uC in an atmosphere of
5% CO2, 1% O2 and 94% N2, and synchronized using 5%
sorbitol. Late-stage parasites (36–40 hr) were isolated (.95%
purity) from uninfected RBCs with a MAC magnet separation
column (Miltenyi Biotech). Schizonts were treated with Epox-
ysuccinyl-L-leucylamido(4-guanidino)butane (E64), as described
previously [34]. Briefly, parasites were incubated with 10 mM E64
(Sigma-Aldrich) overnight for up to 12 hrs. Schizonts were
pelleted at 1,9006g for 8 min, and resuspended in 3 mL THP-1
media and filtered through a 1.2-mm Acrodisc 32-mm syringe filter
(Pall). Filtered merozoites were separated from haemozoin by
passing the 3 mL suspension twice over an equilibrated LS MACS
Column (Miltenyi Biotech), followed by a final wash of the column
with 1.5 mL THP-1 media. Merozoites were stained with
ethidium bromide (EtBr) for 30 mins (10 mg/mL, Bio-Rad) at
room temperature, followed by two washes in 10 mL THP-1
medium, with centrifugation at 4,0006g for 8 mins. Merozoites
were resuspended in 3 mL THP-1 medium, and absolute number
determined using Count-Bright Absolute Counting Beads (Invi-
trogen) as per manufacturer’s protocol.
Phagocytosis Assay
EtBr-stained merozoites were suspended in 150 mL THP-1
medium per well and incubated in FBS-coated 96-well U-bottom
plates with serum or plasma samples for 40 mins at 22uC in the
dark. Various merozoite:THP-1 cell ratios were tested ranging
from 50:1 to 1:1. Different plasma dilutions ranging from 1/10 to
1/561028 were also used. Following opsonisation, 50 mL aliquots
of merozoites were resuspended and transferred to FBS-coated 96-
well U-bottom plates. THP-1 cells were added at a final
concentration of 56105/mL to make up a final volume of
200 mL per well and each sample was tested in triplicate. Plates
were incubated for 40 mins at 37uC in 5% CO2 1% O2 and 94%
N2 humidified incubator. Phagocytosis was arrested by centrifu-
gation at 5006g for 5 min at 4uC. Cells were washed twice in ice-
cold PBS and fixed in 100 mL 2% paraformaldehyde (PFA).
Samples were acquired (20,000 events) using a FACSCalibur (BD
Bioscience) flow cytometer with HTS plate reader attachment.
Viable cells were gated by forward and side scatter. In experiments
where inhibition of phagocytosis was performed, THP-1 cells were
treated with cytochalasin D at 10 mM for 90 mins prior to addition
to free merozoites. In FcR blocking experiments, THP-1 cells were
incubated with 10 ug/ml of non immune human IgG (Sigma), for
45 mins prior to addition of free merozoites. Percentage phago-
cytosis refers to the % of EtBr positive cells with immune plasma
minus the % positive cells with non-immune plasma.
FITC Stained Merozoite Phagocytosis Assay and
Quenching of Surface Fluorescence
Following filtration and removal of haemozoin, merozoites were
centrifuged at 40006g and stained with 0.1 mg/mL FITC in PBS
for 30 mins at 37uC. Merozoites were washed twice in 15 mL
Opsonising Antibodies to P.falciparum Merozoites
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THP-1 medium, and resuspended in 3 mL THP-1 medium. The
concentration of merozoites was determined using Count-Bright
Absolute Counting Beads (Invitrogen) as described above. FITC
merozoites were opsonised and phagocytosed as per EtBr
phagocytosis assay above, fixed in 50 mL 2% PFA and kept at
4uC until acquisition. To quench surface FITC fluorescence, an
equal volume of trypan blue buffer (0.1 M citrate buffer pH4.0
with 250 mg/mL trypan blue) was added and cells incubated on
ice for 1 minute prior to acquisition. THP-1 cells stained with
CD14-FITC (clone M5E2, BD Biosciences) were used as a positive
control for quenching efficiency. Samples were acquired (20,000
events) using a FACSCalibur (BD Bioscience) flow cytometer.
Anti-sera, SDS-PAGE and Immunoblot Analysis
Anti-MSP-3 and anti-MSP-6 anti-sera were raised in mice
against full length purified proteins. Rabbit anti-sera to MSP-119
was generated as described previously [35]. Rabbit AMA-1 anti-
sera was a gift from A. Hodder. 3D7 schizonts, merozoites after
filtration and after EtBr staining were separated on 4–12% SDS–
NuPAGE gels (Invitrogen) and transferred to PVDF membrane
(Invitrogen). Reactvity of anti-MSP-3, MSP-6 and AMA-1 was
compared by immunoblotting and detection by anti-rabbit or
mouse IgG horseradish peroxidase (HRP) conjugate (Millipore),
and visualised via enhanced chemiluminescence (ECL, Amersham
Biosciences).
Indirect Immunofluorescence Assay (IFA)
3D7 merozoites were washed twice and fixed with 0.0075%
glutaraldehyde/4% PFA (ProSciTech, Australia) for 30 mins at
22uC and air-dried onto slides. Fixed parasites were subsequently
blocked overnight in 3% BSA (Sigma) in PBS at 4uC. Parasites
were then incubated with rabbit antisera to MSP-3 and MSP-119
in 3% BSA/PBS for 1 hr at 22uC. Following two washes in PBS,
parasites were stained with Alexa Fluor-594 conjugated anti-
mouse secondary antibody (Invitrogen) for 1 hr at 22uC. After
three washes in PBS, parasites were mounted in VectaShieldH
(Vector Laboratories) with 0.1 ng/mL 49,6-diamidino-2-phenylin-
dole, DAPI (Invitrogen). Fluorescence images were obtained using
a Plan-Apochromat 1006/1.40 oil immersion Phase contrast lens
(Zeiss) on an AxioVert 200 M microscope (Zeiss) equipped with an
AxioCam Mrm camera (Zeiss). Images were processed using
Photoshop CS5 (Adobe).
Statistics
Data were analysed using Graph Pad Prism v5. For compar-
isons between different THP-1 cell treatment conditions, a two-
tailed student t-test was performed with 95% confidence. For
comparison of inter-assay variability, a non-parametric Spearman
correlation and Bland-Altman mean-difference test were per-
formed with 95% confidence intervals.
Results
Merozoite Isolation Technique Removes Haemozoin and
Maintains Merozoite Surface Integrity
When added to late trophozoite stages, the protease inhibitor
E64 prevents schizont rupture, resulting in parasitophorous
vacuolar membrane enclosed merozoite structures, or PEMS
[36]. A recent method utilizes E64 to generate PEMS, which are
ruptured by filtration to release viable merozoites and haemozoin
crystals [37]. We have adapted this method to produce large yields
of merozoites for subsequent use in phagocytosis assays. The
presence of haemozoin crystals in solution with merozoites
promoted formation of large aggregates of haemozoin and
merozoites. Haemozoin can be removed by passing the filtrate
over magnetized columns [34], and we have refined this technique
to enable isolation of merozoites free of haemozoin for phagocy-
tosis assays (Figure 1a). To quantify uptake of merozoites into
THP-1 cells, merozoites were stained with EtBr and enumerated
by flow cytometry using fluorescent counting beads (Figure 1b).
We sought to determine whether the integrity of the merozoite
surface coat was impaired by multiple washing steps required for
EtBr staining. Western blot and immunofluorescence assay
confirmed peripherally associated merozoite surface proteins
MSP-3 and MSP-6 were not shed or lost during washing steps
(Figure 1c and 1d). In addition, GPI-anchored MSP-119 and
transmembrane AMA-1 were also maintained. Detailed investi-
gations of rhoptry, microneme and merozoite surface protein
expression in filtered merozoites have been reported elsewhere
[34,37].
Ethidium Bromide Fluorescence Marks Internalised
Merozoites within THP-1 Cells
A strong phagocytosis response was observed for merozoites
opsonised with immune plasma, with low levels of background
EtBr positive cells observed with non-immune plasma
(Figure 2a). Fluorescence with non-immune plasma was
consistently equivalent to non-opsonised controls, and hence
merozoites opsonised with non-immune plasma were included
as a negative control in each experiment. A phagocytosis
response was also observed using GFP expressing D10 parasites
[38], demonstrating application to other lines of P. falciparum
(data not shown), however utilizing an EtBr stain allows the
assay to be adapted to any parasite line or isolate. To test
whether merozoites were phagocytosed by THP-1 cells and not
adherent to the cell surface, isolated merozoites were FITC-
stained and phagocytosis assay performed, and an acidic trypan
blue (TB) buffer added prior to flow cytometry [39]. TB has
been shown to quench only surface FITC staining, providing a
useful tool to differentiate adherent from internalized particles
[40]. To confirm that TB buffer was able to quench surface
FITC fluorescence from THP-1 cells, monocytes were stained
with FITC-conjugated anti-CD14 antibody. Incubation of
monocytes with TB buffer efficiently quenched FITC fluores-
cence associated with surface staining using this antibody
(Figure 2b). To confirm antibody-dependent phagocytosis,
merozoites were then stained with EtBr or FITC and utilized
in the phagocytosis assay (Figure 2a and c). When FITC stained
merozoites incubated with non-immune plasma were added to
THP-1 cells and quenched by TB buffer, fluorescence was
indistinguishable from THP-1 cells alone (Figure 2c). Following
quenching, the FITC mean fluorescence intensity (MFI) also
decreased in THP-1 cells added to immune plasma opsonised
merozoites. However, the percentage of phagocytosis observed
with FITC-quenched THP-1 cells added to immune plasma
opsonised merozoites, after non-immune background subtrac-
tion, was comparable to the percentage of phagocytosis
demonstrated with EtBr stained merozoites at the ratio of 3:1
and 10:1 merozoites:THP-1 cells (Figure 2d).
Phagocytosis of Merozoites is an Active Process
Requiring Fc Receptor Mediated Interactions
Cytochalasin D is an actin polymerization inhibitor, which
prevents cytoskeletal rearrangements necessary for phagocytosis.
THP-1 cells were treated with Cytochalasin D and EtBr
fluorescence was reduced to a level equivalent to the non-immune
serum controls (Figure 2e), indicating active phagocytosis. To
Opsonising Antibodies to P.falciparum Merozoites
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determine the importance of Fc Receptor phagocytosis, FcR were
blocked with high concentrations of non-specific IgG. FcR blocked
THP-1 cells showed a complete reduction in phagocytic capacity,
indicating FcR-antibody interaction is the underlying mechanism
for merozoite phagocytosis observed (Figure 2e).
Figure 1. Isolated merozoites maintain surface coat integrity. A) E64-treated schizonts were filtered to release free merozoites and
haemozoin crystals, and the filtrate was passed over magnetic columns. Merozoite purification was confirmed by Giemsa-stained smears of i) filtrate,
ii) retained haemozoin and iii) purified merozoites. B) Merozites were stained with EtBr and enumerated by flow cytometry. C) Washed Merozoites
retained surface proteins MSP-3, MSP-6 and AMA-1 by western blot (S: purified Schizonts; M: filtered merozoites; SM: EtBr stained merozoites). D)
Merozoite surface proteins are maintained during merozoite isolation and wash steps as shown by surface localisation of MSP-3 and MSP119 by
immunofluorescence microscopy. Antigens were stained with Alexa-594 and the nucleus with DAPI (panels in order Alexa549; DAPI; brightfield;
Alexa549/DAPI; merge).
doi:10.1371/journal.pone.0051692.g001
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Figure 2. Phagocytosis by THP-1 cells is antibody and Fc Receptor dependent. A) EtBr stained merozoites were incubated with i) non-
immune plasma or ii) immune PNG plasma, and were added to THP-1 cells. THP-1 cells were gated by forward and side scatter, and EtBr fluorescence
was determined by flow cytometry. A non-immune control sample was used to set the EtBr positive gate. B) THP-1 cells were stained with anti-CD14
antibody and treated with trypan blue (TB) buffer which quenched all surface FITC fluorescence (black:THP-1 cells only, white: CD14-FITC stained THP-
1, grey: CD14-FITC stained THP-1 with TB buffer). C) FITC stained merozoites were opsonised with i) non-immune or ii) immune PNG plasma and
added to THP-1 cells. FITC fluorescence was measured by flow cytometry before and after quenching, and phagocytosed merozoites were resistant to
quenching (black:THP-1 cells only, white: fluorescence with FITC stained merozoites, grey: fluorescence with FITC stained merozoites after TB buffer).
D) The % phagocytosis measured for EtBr stained merozoites was equivalent to FITC stained merozoites after quenching. Opsonised EtBr stained and
FITC stained merozoites were added to THP-1 cells at 3:1 and 10:1 merozoite:THP-1 ratios. E) Phagocytosis is active and Fc Receptor dependent. THP-
1 cells were treated with cytochalasin D (CytoD) or blocked with non-specific IgG prior to addition to immune plasma opsonised merozoites in the
phagocytosis assay. Each point represents the mean 6 standard error. *, p,0.05; **, p,0.01; ***, p,0.005.
doi:10.1371/journal.pone.0051692.g002
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Phagocytosis Assay Optimisation
THP-1 cells are very efficient phagocytes for latex particles,
platelets, erythrocytes and trophozoites [33,41–43]. Different
particle-to-THP-1 cell ratios have been described in phagocytosis
assays. The number of merozoites required was optimized, and
ratios from 1:1 to 50:1 merozoite:THP-1 cells were tested.
Merozoite phagocytosis was very robust in the presence of
immune plasma, with phagocytosis measurable as low as one
merozoite per THP-1 cell. Phagocytosis reached a maximum at
20:1 merozoites:THP-1 cell. The lower dilution of 4:1 merozoi-
tes:THP1 was chosen for subsequent assays as this is within the
dynamic range useful for detecting individual differences between
diverse sample sets (Figure 3a).
Assay Sensitivity and Reproducibility
Plasma volumes were titrated to determine the dynamic range
in which variation in responses between individuals could be
detected. Serial dilutions of a pool of plasma from 22 PNG
children were performed and the phagocytosis readout determined
(Figure 3b). High concentrations of plasma caused a reduction in
phagocytosis capacity consistent with the pro-zone effect [44], an
effect known to influence THP-1 phagocytosis [33]. The dynamic
range of the assay occurred between 1/6000 and 1/150,000
Figure 3. Efficient merozoite phagocytosis at low antibody concentrations. A) Increasing numbers of EtBr labeled merozoites were
incubated with a pool of immune plasma from PNG children and then added to THP-1 cells. The % phagocytosis was determined by flow cytometry.
The ratio of 4:1 was chosen for subsequent assays, and is indicated by the arrow above. B) Titration of a pool of immune plasma from PNG children
for opsonising activity using the 4:1 merozoite:THP-1 cell ratio. % phagocytosis was determined by flow cytometry. The chosen dilution, 1/30,000, is
indicated by an arrow above.
doi:10.1371/journal.pone.0051692.g003
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dilution. The optimal dilution chosen was 1/30,000 as phagocy-
tosis in this range was still robust but was positioned half way
between the maximum and minimum responses. Using these
optimized assay conditions, plasma samples from 22 PNG
children aged 5–10 years old were tested. A 1/50 dilution of
PNG adult plasma was used as a positive control for maximal
responses. These assay conditions enabled resolution of differences
between individuals, detecting low, high or intermediate responses
(Figure 4a). When these plasma samples were utilized on different
experimental days with different batches of THP-1 cells and
merozoites, we detected outstandingly reproducible and correlated
responses by Spearman’s correlation (Figure 4b, rS = 0.927,
p,0.0001) and Bland-Altman test (Figure 4c).
Assay Detects Rapid Opsonisation
To further assess the efficacy of opsonisation, the pool of PNG
child plasma was tested at several dilutions with or without a pre-
incubation step (i.e. merozoites and plasma were pre-incubated or
added simultaneously to wells containing THP-1 cells). At the four
dilutions tested, no difference was observed between the two
conditions (Figure 5). These findings further highlight that
merozoite opsonisation leading to phagocytosis occurs very rapidly
and is highly efficient.
Discussion
Merozoite surface proteins are attractive malaria vaccine
candidates due to their exposure to the immune system, and the
ability of antibodies directed to such surface antigens to inhibit
parasite development. Humoral responses against merozoite
surface antigens can function to inhibit invasion directly [45,46]
or to opsonise merozoites leading to phagocytosis [29], respiratory
burst [47] or ADCI [48]. Functional immunological assays that
measure these key effector mechanisms are more likely to reveal
associations with clinical immunity than serology alone [49].
Several vaccines are in development that may require leukocyte
co-operation for vaccine-induced antibodies to provide clinical
protection [50,51]. Thus, there is a clear need for better assays to
test the potential protective efficacy of these mechanisms.
Phagocytosis is a complementary mechanism to ADCI for
cytophillic IgG to produce an antibody mediated cellular
protective response against merozoites. There has been limited
study in this area, however, due to the difficulties in isolating
merozoites from culture supernatants. Merozoites isolated in this
way are collected over several hours of schizont rupture and
extensive handling and washing steps are required. The technique
optimized here enables a high yield of fluorescently labeled
merozoites, with surface coat intact, to be isolated by filtration and
magnetic separation from haemozoin. Haemozoin has long been
studied for its ability to modulate immune responses both with
stimulatory [52–55] and inhibitory [56,57] effects. These effects
are especially pronounced in monocytes which rapidly phagocy-
tose haemozoin, leading to rapid oxidative burst [52] whilst
inhibiting repeat phagocytosis [58]. In addition to these effects,
haemozoin promotes the formation of merozoite-haemozoin
aggregates, and hence it is critical to perform haemozoin free
merozoite phagocytosis assays.
Previous investigations of merozoite phagocytosis have used
mostly microscopy readouts [25–28], or FITC stained merozoites
and flow cytometry [29]. EtBr staining is more specific for
merozoites than protein stains such as FITC, allowing confidence
that fluorescence is due to intact merozoites and not other parasite
and red blood cell material.
Figure 4. Optimised Phagocytosis Assay is sensitive and
reproducible. A) Percentage phagocytosis for 22 plasma samples
from PNG children, compared to a pooled PNG adult positive control. B)
Interassay comparisons as determined by Spearman Correlation, or (C)
Bland-Altman test.
doi:10.1371/journal.pone.0051692.g004
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Previous merozoite phagocytosis assays and current ADCI
assays use primary monocytes or neutrophils. Primary human
phagocytic cells display variable capacities for phagocytosis,
exhibit FcR polymorphisms, and can be modulated by exposure
to inflammatory cytokines in vivo. These factors limit the utility of
primary phagocytes in in vitro assays to measure antibody
functions. THP-1 cells have been used extensively in phagocytosis
assays after chemical differentiation [59,60], however these cells
perform non-FcR mediated phagocytosis [61]. Undifferentiated
THP-1 cells are non-adherent enabling flow cytometric readout
[41,59,60]. Undifferentiated THP-1 cells only phagocytose
through Fc receptors, where FccRI, FccRIII, and all isoforms of
FccRII are expressed [32,33,62]. As all phagocytic Fc receptors
are expressed, THP-1 present an ideal cell type for investigating
opsonising antibodies and the contribution of Fc receptors in
merozoite phagocytosis. As demonstrated in this paper, the THP-1
cell line can robustly and reproducibly phagocytose merozoites,
but only in the presence of immune plasma.
Using the optimized phagocytosis assay, merozoite phagocytosis
was very efficient and required minimal amounts of antibody.
Saturated phagocytosis was observed using more than a hundred
times less plasma than existing studies of merozoite phagocytosis
[27,29], or growth inhibitory assays (GIA) [63,64]. Significant
further dilution was required to reach a non-saturating range,
using a 1/30,000 dilution. This requirement for dilute concentra-
tions of plasma to elicit a functional response from monocytes is
within the range observed using ADCI, where as low as 700 pM
IgG inhibited parasite growth [17]. This finding stresses the
importance of determining the dynamic range for in vitro antibody
functional assays that serve as a correlate for immunity. IgG2,
IgG4 and IgM have been reported to inhibit binding of cytophillic
IgG to malarial antigens [65–67]. As this assay utilizes plasma,
rather than purified IgG, it enables measurement of opsonizing
responses in the presence of inhibiting antibody isotypes and
subclasses, which are present in vivo.
As noted, functional immunity to P. berghei requires phagocytes
[22], and appropriate FcRs are required for passive transfer of
immunity by human monoclonal antibodies directed towards the
merozoite antigen MSP-1 [30]. In humans, P. falciparum mature
parasites sequester, hence merozoite egress and invasion occurs in
deep vascular beds (not in peripheral circulation) where they may
come into contact with effector cells. As merozoite invasion of red
cells can occur rapidly, phagocytosis must also be highly efficient if
it is to be protective. We have shown that opsonisation leading to
merozoite phagocytosis is rapid and efficient, but the contribution
of merozoite phagocytosis to immune protection remains to be
determined. Although the degree of merozoite phagocytosis was
found to increase with immune status in a few African individuals
[25], the causal link between this functional response and
decreased disease risk has not been rigorously tested. The
merozoite phagocytosis assay described here has sufficient
throughput and minimal requirements for plasma to allow use in
large cohort studies in order to determine relative risk and to assess
vaccine efficacy and immunogenicity.
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